The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954

Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs

INTRODUCTION

Centrally muscle relaxants (CMRs) are used mainly for treating muscle spasticities of neurological origin, and painful muscle spasms due to rheumatologic conditions. Their use is frequently associated with dose-limiting adverse effects. New drugs with improved side-effect characteristics are badly needed. However, there is no general agreement in the pharmacological literature on what methods are adequate to assess CMR effect and side effects in behaving rodents, which may hinder the development of new drugs. Here we report on the establishment of a simple pharmacological test battery, which was used to compare efficacies and side effect profiles of 11 compounds with central muscle relaxant action, in mice (intraperitoneal application).

METHODS

For measuring muscle relaxant activity, (1) a new tremor model (GYKI 20039-induced tremor) and (2) the morphine-induced Straub-tail assay were used. The former, newly developed method has advantages over harmaline- or LON-954-induced tremor. For detecting side effect liability (ataxia, sedation, impairment of voluntary motor functions), (1) the rota-rod test, (2) measurement of spontaneous motility, (3) the weight-lifting test and (4) the thiopental sleep test were used.

RESULTS

Among the 11 muscle relaxant compounds tested (tolperisone, eperisone, silperisone, diazepam, baclofen, tizanidine, afloqualon, mephenesin, zoxazolamine, memantine and carisoprodol), the calculated safety ratios (i.e. ID50 for side effect/ID50 for muscle relaxant effect) varied in a wide range. Silperisone seems to have the most advantageous profile (safety ratios range between 1.7 and 3.3 in the different pairs of assays) compared to the other tested drugs with lower (one or more ratios below 1.5, and often far below 1) and more varying ratios.

DISCUSSION

Therapeutic indices calculated from the results of these in vivo experiments for the clinically used muscle relaxants are in agreement with their adverse effect profiles in humans. Thus the present test battery seems to be suitable for predicting the possible clinical utility of newly synthesized compounds.

Role of GABA receptor complex in low dose lindane (HCH) induced neurotoxicity: neurobehavioural, neurochemical and electrophysiological studies

Lindane is widely used as an insecticide and scabicide in mammals. High doses in chronic exposures caused hyperexcitability and convulsions and impaired motor activity involving GABA-ergic mechanism. To investigate the role of GABA/Benzodiazepine mechanism in the neurotoxicity of low doses of lindane, rats were administered 2, 3, or 5 mg/kg orally for 90 days and behavioural, electrophysiological, and neurochemical studies were conducted. The animals exposed to lindane exhibited increased geotaxis and decreased spontaneous drug-induced locomotor activity (which further potentiated by phenobarbitone and increased after leptazol). The EEG of the treated rats showed high voltage slow-wave activity (HVSA) patterns with occasional spindles (9-10 HZ-amplitude of 100 uv). A significant increase (p < 0.01) in GABA levels in cerebellum and significant increase in benzodiazepine receptors in cerebellar membrane measured by (3H)flunitrazepam binding were observed in the animals exposed to 3 and 5 mg lindane. The study suggests that low dose chronic exposure of lindane causes neurobehavioral, neurochemical, and electrophysiological effects involving GABA-ergic mechanism(s).

Animal pharmacology of guanfacine

The pharmacologic data obtained from animal experiments with guanfacine, a novel, centrally acting antihypertensive agent, are reviewed. When given orally, guanfacine lowers systemic blood pressure in conscious DOCA-NaCl-hypertensive rats, Grollman rats and spontaneously hypertensive rats in a dose-dependent manner. It is also effective in renal hypertensive cats. Guanfacine reduces blood pressure in cats, rabbits and rats after injection into the lateral cerebral ventricle and in dogs after infusion into the vertebral artery at intravenously ineffective doses. Vagally mediated reflex bradycardia in dogs is enhanced. The preganglionic splanchnic (sympathetic) nerve activity is reduced in cats. In rats, guanfacine reduces the noradrenaline turnover in the brain stem. All these findings indicate a central site of action. Peripheral alpha-adrenoceptor stimulant properties of guanfacine have been demonstrated in various studies. In addition to postsynaptic stimulant effects, presynaptic guanfacine-induced inhibition of sympathetic heart nerve stimulation is antagonized by rauwolscine but not by prazosin, indicating a highly preferential alpha 2-agonistic presynaptic action of the drug. In receptor binding studies using rat cortex membranes and human platelets, guanfacine exhibited a high selectivity for alpha 2 adrenoceptors. Guanfacine has the advantage over other centrally acting antihypertensives of being less sedative and causing no rebound hypertension after discontinuation of treatment. The latter is mainly due to its pharmaco-kinetic properties.

Harmine-, LON-954- and 5-hydroxytryptophan-induced tremors in rats withdrawn from ethanol

The tremors induced by harmine, LON-954 (N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride) and 5-hydroxytryptophan (5-HTP) were studied in control rats and in rats withdrawn for 16-48 hrs from 6 to 9 days' ethanol administration. The frequencies and the intensities of the tremors were determined electronically. In control rats the frequency spectra of the tremors induced by harmine (20 mg/kg) and LON-954 (10 mg/kg) showed a narrow peak frequency at about 10 Hz. Atropine (1.2 mg/kg) altered neither the frequency nor the intensity of these tremors. 5-HTP (50 mg/kg) when given 3.5 hrs after iproniazid (100 mg/kg) induced tremor with peak frequencies at 6-7 Hz and 12 Hz. In ethanol-withdrawn rats treated with harmine or LON-954 the frequency analysis of tremor revealed a narrow peak frequency at about 12 Hz, which was neither the characteristic frequency of ethanol withdrawal tremor (6 Hz) nor that of harmine or LON-954 (10 Hz). The intensity of both harmine- and LON-954-induced tremor was significantly increased in ethanol-withdrawn rats. The ethanol-withdrawn rats were markedly sensitized to the effect of iproniazid+ 5-HTP, shown by deaths. The peak frequencies of this tremor were the same as those in control rats. The results suggest that harmine-induced tremor involves a dopaminergic-5-HT'ergic imbalance and the tremor induced by LON-954 a dopaminergic-cholinergic imbalance in the brain. The tremor in ethanol-withdrawn rats seems to be mediated by alterations in the activity of the cerebral 5-HT'ergic system.

Effect of electroconvulsive shock on central cholinergic (muscarinic) receptors

Sensitivity of central cholinergic (muscarinic) receptors was studied in rats after application of single and repeated (once daily for 7 days) electroconvulsive shocks (ECS). Oxotremorine-induced tremor was significantly enhanced after single as well as chronic exposure to ECS; [3H]QNB binding in frontal cortex was also significantly increased by chronic ECS. The results indicate that ECS develops supersensitivity in central muscarinic receptors.

Potentiation of LON 954 tremor by typical and atypical neuroleptics--an indication of striatal dopamine antagonism

Tremor produced in laboratory mice by the benzylimidoylurea derivative LON 954 was potentiated in a dose-dependent manner by a variety of typical and atypical neuroleptics. The most effective agents in this respect were those shown by other workers to have a selective action at dopamine receptors, notably the butyrophenones, thioxanthines and fluphenazine. Chlorpromazine and prochlorperazine produced inconsistent effects while clozapine and loxapine respectively delayed and prolonged the peak tremor response. While these findings support primary involvement of striatal dopaminergic mechanisms in LON 954 tremorogenesis, a reduction in cyclic AMP levels may be an important factor in the observed effects.